Due to the capability of Flt3L to expand cross-presenting-DC populations, Flt3L has been assessed in both healthy and cancer patients as a candidate immunotherapeutic (20, 21), and has been previously incorporated into various therapeutic vaccine designs and treatment strategies (22–28). The gene discussed is FLT3LG; the disease is cancer.